DUBLIN, Sept. 18, 2018 /PRNewswire/ --
The "Global Premature Ejaculation Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.
The global premature ejaculation treatment market was valued at US$ 1,666.1 Mn in 2017, and is expected to reach US$ 3,541.4 Mn by 2026, expanding at a CAGR of 8.8% from 2018 to 2026.
The disease etiology of premature ejaculation is not clearly understood. The theories which have been postulated for the occurrence of premature ejaculation in men are rapid masturbation during adolescence, performance anxiety, having less sexual experience and passive aggressiveness. However, these theories are supported with little or no evidence.
Urologists throughout the globe believe that the nucleus paragigantocellularis of the neuronal cells are involved in premature ejaculation. It causes the patient and his sexual partner emotional and relationship stress. It can be classified as primary or lifelong premature ejaculation and acquired or secondary premature ejaculation.
The other factors which can cause premature ejaculation are inflammation of prostate or urethra, inherited traits and abnormal levels of neurotransmitters. Tremendous technological developments have taken place in the formulation research and development segment to provide drugs with maximum efficacy and minimal side effects.
Currently the selective serotonin reuptake inhibitors dominate the premature ejaculation treatment market. It comprises of drugs such as sertraline, paroxetine, fluoxetine and citalopram. It has quick response as it reduces the serotonin uptake at presynaptic neuronal cells and increases the serotonin concentration at postsynaptic receptor cells, thereby delaying the intravaginal ejaculation time.
Topical anesthetic agents will showcase excellent growth during the forecast period owing to its availability as creams, sprays and condoms which provides climax control by controlling the afferent-efferent reflex pathway and delaying the ejaculation.
Oral route of administration is preferred by patients suffering with premature ejaculation disorder on account of faster onset of action and is popular among urologists to be prescribed for treating acute premature ejaculation disorder.
Topical route of administration is growing at a rapid pace due to better patient compliance and effectiveness in increasing the ejaculation latency time by reducing the sensitivity at glans penis.
Rising prevalence of relationship problems, sexual performance anxiety and illicit drug abuse controls the premature ejaculation treatment market growth in North America. Asia Pacific will be performing with excellent market growth owing to key factors such as rising public awareness regarding premature ejaculation and availability of generic drugs at lower price.
Key Market Highlights
- Increasing number of patients suffering with premature ejaculation disorders
- Technological advancement in the preparation of anesthetic agents such as aerosol sprays and condoms to increase intravaginal latency time
- Rising public awareness regarding premature ejaculation in both patients and physicians
Key Topics Covered
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Scope
1.3. Research Methodology
1.4. Market Segmentation
Chapter 2. Executive Summary
2.1. Global Premature Ejaculation Treatment Market Portraiture
2.2. Global Premature Ejaculation Treatment Market, by Drug Class, 2017 (US$ Mn)
2.3. Global Premature Ejaculation Treatment Market, by Route of Administration, 2017 (US$ Mn)
2.4. Global Premature Ejaculation Treatment Market, by Geography, 2017 (US$ Mn)
Chapter 3. Premature Ejaculation Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Premature Ejaculation Treatment Market, by Key Players, 2017
Chapter 4. Global Premature Ejaculation Treatment Market, by Drug Class
4.2. Selective Serotonin Reuptake Inhibitor
4.3. Tricyclic Antidepressant
4.4. Topical Anesthetic Agent
4.5. Phosphodiesterase Type 5 Inhibitors
4.6. Others (Beta-adrenergic Blockers, Analgesic Opioids)
Chapter 5. Global Premature Ejaculation Treatment Market, by Route of Administration
5.2. Oral Route
5.3. Topical Route
Chapter 6. Global Premature Ejaculation Treatment Market, by Geography
6.2. North America Premature Ejaculation Treatment Market Analysis, 2016-2026
6.3. Europe Premature Ejaculation Treatment Market Analysis, 2016-2026
6.4. Asia Pacific Premature Ejaculation Treatment Drugs Market Analysis, 2016-2026
6.5. Latin America Premature Ejaculation Treatment Market Analysis, 2016-2026
6.6. Middle East & Africa Premature Ejaculation Treatment Market Analysis, 2016-2026
Chapter 7. Company Profiles
7.1. Absorption Pharmaceuticals
7.3. Allergan plc
7.4. Bayer AG
7.5. Eli Lilly & Company
7.6. GlaxoSmithkline plc
7.7. Innovus Pharmaceutical
7.8. Merck & Co., Inc.
7.9. Pfizer, Inc.
7.10. Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/2nvvrt/the_premature?w=5
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets